Companies in #GLP-1 / Glucagon Dual Agonists

Sciwind Biosciences is a Chinese clinical-stage biopharmaceutical company developing long-acting peptide therapeutics for metabolic disease, with a lead asset in obesity based on a once-monthly GLP-1/glucagon dual agonist formulation. The company has signed two Western licensing deals for its obesity candidate and is open to additional geographic partnerships as it seeks to expand beyond the Chinese market.